CD14 and B-cell chronic lymphocytic leukemia: Furthermore, when patients were divided based on combinations of good (M-CLL/CD38low) or poor (U-CLL/CD38high) prognosis markers, the M-CLL/CD38low and U-CLL/CD38high subgroups of patients exhibited significantly higher CD14+HLA-DRlow/− MDSC frequency compared with the controls (both P<0.0001), and the CD14+HLA-DRlow/− frequency in the U-CLL/CD38high subgroup was higher than in the M-CLL/CD38low subgroup (P=0.0052) (Fig. 2E).